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Abstract Theaimofthisretrospectivestudywastodetermine
the prevalence of lysosomal storage disorders (LSDs) in the
Czech Republic. The data on cases diagnosed between 1975
and 2008 were collected and analyzed. The overall prevalence
of LSDs in the Czech population (12.25 per 100,000) is
comparable to that reported for the countries with well-
established and advanced diagnostics of LSDs such as the
Netherlands (14 per 100,000), Australia (12.9 per 100,000)
and Italy (12.1 per 100,000). Relatively higher prevalence of
LSDs was reported in the north of Portugal (25 per 100,000).
Thirty-four different LSDs were diagnosed in a total of 478
individuals.GaucherdiseasewasthemostfrequentLSDwitha
birth prevalence of 1.13 per 100,000 births. The most frequent
LSD groups were lipidoses, mucopolysaccharidoses, and
neuronal ceroid lipofuscinoses, with combined prevalences of
5.0, 3.72, and 2.29 per 100,000 live births, respectively.
Glycoproteinoses (0.57 per 100,000 live births), glycogenosis
type II (0.37), and mucolipidoses (0.31) rarely occur in the
Czech population, and a range of other LSDs have not been
detected at all over the past three decades. Knowledge of the
birthprevalence and carrier frequency of particular disorders is
important in genetic counselling for calculation of the risk for
the disorder in the other members of affected families. Earlier
diagnosis of these disorderswill permit timely intervention and
may also result in lowering of the number of newborns with
LSDs.
Introduction
Following the discovery of the lysosome by the Nobel Prize
winner Christian de Duve in 1955 (De Duve et al. 1955),
research into the biochemistry, molecular biology and
pathology of the lysosomal system unravelled many of its
functions.
Nowadays, genetic lysosomal storage disorders (LSDs)
represent a group of about 50 disorders (Scriver et al. 2001;
Staretz-Chacham et al. 2009). All of them are characterized
by intralysosomal accumulation of compound(s), e.g.,
enzyme substrates or products, mishandled bioconjugates,
or segregated cytoplasmic components, in a variety of cell
types and tissues. Most LSDs result from a deficient
enzyme activity caused by a mutation in the gene encoding
either the relevant enzyme, protecting protein, protein
activators, or the endoplasmic reticulum–Golgi enzyme
systems responsible for proper protein posttranslational
modification. However, some are caused by dysfunction
of the lysosomal system itself due to mutations in genes
encoding lysosomal membrane components or components
closely associated with the lysosomal system (Saftig 2005;
Jalanko and Braulke 2009). The number of lysosomal
enzymes and non-catalytic proteins reported in the literature
has steadily increased and, therefore, more defects in the
lysosomal systemare expectedto bediscovered. The progress
in the research into LIMP-2 deficiency serves as a recent
example (Balreira et al. 2008;B e r k o v i ce ta l .2008).
Overall frequencies of occurrence of LSDs have been
reported for several countries (Meikle et al. 1999; Poorthuis
et al. 1999; Applegarth et al. 2000; Dionisi-Vici et al. 2002;
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groups (e.g., mucopolysaccharidoses, (MPS): Nelson et al.
2003; Baehner et al. 2005; Malm et al. 2008; lipidoses:
OzkaraandTopcu2004; neuronal ceroid lipofuscinoses, NCL:
Claussen et al. 1992), or on particular LSDs (e.g., MPS I:
Moore et al. 2008; metachromatic leukodystrophy and Krabbe
disease: Heim et al. 1997). The frequency of LSDs as a group
varies among populations from 7.6 to 25 per 100,000 (Meikle
et al. 1999; Poorthuis et al. 1999; Applegarth et al. 2000;
Dionisi-Vici et al. 2002;P i n t oe ta l .2004).
The aim of this study was to calculate the birth prevalence
and carrier frequencies of LSDs in the Czech Republic
population, and to compare our results with reported
epidemiologic data from other populations.
Patients and methods
We analyzed data from individuals who had been diagnosed
with a LSD at the Institute of Inherited Metabolic Disorders in
Prague between 1975 and 2008. Our Institute is the only
laboratory providing diagnostic testing for LSDs, including
prenatal testing, in the Czech Republic. The patients had been
referredto,ortheirbloodsampleshadbeensentto,theInstitute
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Fig. 1 Relative rate oflysosomal
storage disorders in the Czech
Republic. MPS Mucopolysac-
charidosis, NCL neuronal
ceroidlipofuscinosis, GSD II
glycogenosis type II, ML
mucolipidosis, GP glycoprotei-
nosis, NPA/B/C Niemann-Pick
A/B/C, MLD metachromatic
leukodystrophy, CESD
cholesterol ester storage disease,
MSD multiple sulphatase
deficiency, GM1 GM1
gangliosidosis, GM2 GM2
gangliosidosis (Tay-Sachs and
Sandhoff diseases), β-Man
β-mannosidosis, α-Man
α-mannosidosis, ISSD infantile
sialic acid storage disease
388 J Inherit Metab Dis (2010) 33:387–396by Departments of Paediatrics, Neurology, Haematology,
Cardiology, Nephrology, Dermatology, Gastroenterology,
Ophthalmology, Pathology, and Clinical Genetics from hospi-
tals all over the country.
The initial diagnosis of most LSDs was based on
demonstration of accumulated substrates (e.g., sphingolipids,
oligosaccharides, or glycosaminoglycans) in tissues and/or
body fluids using chromatographic or electrophoretic methods,
or on histological proof of storage. The definite diagnosis was
made by demonstrating the deficiency of the relevant enzyme
and/or presence of pathogenic mutation, and/or by detection of
undegraded substrate by loading tests in cell cultures.
Mucolipidosis II was confirmed by detecting elevated activities
of multiple lysosomal enzymes in serum and by molecular
analysis. Patients with unspecified types of MPS or NCL, who
had died before the availability of confirmatory tests, were also
included in the birth prevalence calculation. Their diagnosis
was based on biochemical analyses of storage compound,
evaluation of clinical data, and histochemical and/or ultrastruc-
tural examinations of samples obtained at biopsy or autopsy.
For the calculation of the prevalence, we used the method
published by Poorthuis et al. (1999). The prevalence was
calculated as the total number of patients diagnosed with a
particular LSD, divided bythetotal numberof live birthsin the
same period, as was the birth period of the diagnosed cases
(i.e.,thebirthperiodistheintervalbetweentheyearofthebirth
of the oldest patient and the year of the birth of the youngest
patient). Birth prevalence was expressed as the number of
patients per 100,000livebirths.The totalnumberoflive births
in particular years was calculated using birth rates taken from
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Fig. 2 Number of live births (▲) and number of LSD diagnoses (♦)i nt h e
Czech population from 1975 to 2008. In 1985, electrophoretic analysis of
glycosaminoglycans (ELFO GAG) and thin layer chromatography of
oligosaccharides (TLC OLS) in urine were introduced. From 1990
onwards, enzyme assays for mucopolysaccharidoses and glycoproteino-
ses were gradually introduced. Nowadays, laboratory diagnostic methods
for 45 LSDs are available (enzyme and DNA analyses, loading assays)
Table 1 Lipidoses: comparison of data in different populations
Disease Czech Republic Other countries
No. of patients
1975–2008
a
Prevalence
per 100,000
b
Poisson 95%
confidence interval
Carrier
frequency
c×10
3
NL Portugal Australia Turkey
Prevalence per 100,000 live births
Gaucher (all types) 49 1.13 0.61–1.95 6.71 1.16 1.35 1.75 0.45
Niemann-Pick A/B 23 0.33 0.16–0.61 3.65 0.53 0.6 0.4
Niemann-Pick C 54 0.91 0.67–1.21 6.02 0.35 2.2 0.47
Fabry male 49 0.52 (1.0)
d 0.38–0.69 0.01 0.21 0.12 0.86 0.015
Fabry female 78 0.77 0.60–0.98
Krabbe 15 0.40 0.21–0.68 4.0 1.35 1.21 0.71 1
MLD (all types) 25 0.69 0.29–1.38 5.26 1.42 1.85 1.09 1.43
CESD, Wolman 18 0.27 0.15–0.45 3.31 0.19
GM1 gangliosidosis 13 0.26 0.14–0.46 3.25 0.41 0.62 0.26 0.54
GM2 Tay-Sachs 10 0.30 0.14–0.55 3.45 0.41 3.13 0.5 0.23
GM2 Sandhoff 3 0.19 0.04–0.55 2.74 0.34 1.49 0.26 0.95
Lipidoses all types 259
e/337
f 5.0
e/5.77
f 2.79 (3.39)–8.53 (9.51) 6.2 12.6 6.6 4.6
NL Netherlands, MLD metachromatic leukodystrophy, CESD cholesteryl ester storage disease
aTotal number of patients diagnosed between 1975 and 2008
bData for prevalence calculations are in Table 4
cCarrier per 1 live birth
dMale live births only
eFabry females not included
fFabry females included
J Inherit Metab Dis (2010) 33:387–396 389the Czech Statistical Office web page. To avoid underestima-
tion, some patients were not included into the prevalence
calculation (e.g., patients born before 1945 were excluded). If
there was only one patient diagnosed with the disease, the
prevalence was calculated using the number of live births (i.e.,
4,261,897) in the examined period (i.e., between 1975 and
2008),asusedpreviouslybyPintoetal.(2004). Familial cases
and 11 affected fetuses [Fabry disease (1), Niemann-Pick
disease type C (1), MPS I (3), MPS III A (3) and MPS IVA
(3)] were also included in the calculation of birth prevalence.
For some specific LSDs, the patient group consisted of
subgroups with distinct clinical phenotypes (e.g., MLD,
Gaucher disease). Using the method mentioned above, we
calculated the prevalence of the subgroups separately, and the
overall prevalenceofthe specificLSD wasestimatedasa sum
of the prevalences in the subgroups (Poorthuis et al. 1999).
Calculation of the frequency of Fabry disease was done
using two approaches, i.e., excluding and including female
heterozygotes. Exclusion of heterozygotes (n=78) enabled
us to compare the prevalence to other reported male-
specific prevalence data (Meikle et al. 1999; Poorthuis et al.
1999; Ozkara and Topcu 2004; Pinto et al. 2004). Fabry
heterozygotes, who can be as severely affected as male
patients, are nowadays classified as “patients” instead of
“carriers of the defective gene” (Dobrovolny et al. 2005;
Wang et al. 2007; Gibas et al. 2008). Therefore, we also
calculated the prevalence including Fabry females.
Confidence intervals (95%) for the birth prevalences were
estimated from the Poisson distribution using SISA (Simple
Interactive Statistical Analysis) software (Uitenbroek 1997).
Carrier frequency was calculated using the Hardy–Weinberg
equation (Strachan and Read 2004).
Results
In the past three decades, a total of 478 patients have been
diagnosed with one of 34 specific types of LSDs in the Czech
Republic (Fig. 1). The number of diagnosed patients gradually
increased during the study period, from less than 10 cases per
year in the 1970s to 20–30 new cases diagnosed annually in
recent years (Fig. 2). More than half of all LSD patients had a
lipidosis, about one-quarter a mucopolysaccharidosis, and the
remaining quarter suffered from NCL, GSD II, mucolipidoses,
or glycoproteinoses (Fig. 1). The combined birth prevalence
for all LSDs is 12.25 (95% CI 6.25–24.1) per 100,000 live
Table 2 Mucopolysaccharidoses: comparison of data in different populations
Disease Czech Republic Other countries
No. of patients
1975–2008
a
Prevalence
per 100,000
b
Poisson 95%
confidence interval
Carrier
frequency
c×10
3
NL Portugal Australia Germany
Prevalence per 100,000 live births
MPS I 20 0.72 0.44–1.11 5.38 1.19 1.33 1.14 0.69
MPS II 22 0.43 (0.83)
d 0.26–0.65 0.0085 0.67 1.09 0.74 0.64
MPS III A 18 0.47 0.27–0.75 4.31 1.16 0 0.88
MPS III B 1 0.02 0.0–0.13 0.97 0.42 0.72 0.47
MPS III C 5 0.42 0.14–0.99 4.12 0.21 0.12 0.07
MPS III D 0 0 0.1 0.10
MPS III (all types) 24 0.91 0.41–1.87 1.89 0.84 1.42 1.57
MPS IV A 14 0.71 0.38–1.22 5.35 0.22 0.6 0.59
MPS IV B 1 0.02 0.0–0.13 0.97 0.14 0 0
MPS IV (A + B) 15 0.73 0.38–1.35 0.38
MPS VI 2 0.05 0.01–0.18 1.40 0.15 0.42 0.43 0.23
MPS VII 1 0.02 0.0–0.13 0.97 0.24 0 0.05
MPS unspecified
e 32 0.60 0.39–0.87
MSD 3 0.26 0.05–0.77 3.24 0.05 0.48 0.07
MPS all types 119 3.72 1.94–6.93 4.5 4.8 4.44 3.53
NL Netherlands, MPS mucopolysaccharidosis, MSD multiple sulphatase deficiency
aTotal number of patients diagnosed between 1975 and 2008
bData for prevalence calculations are in Table 5
cCarrier per 1 live birth
dMale live births only
eUnspecified cases of MPS were diagnosed on the basis of analysis of glycosaminoglycan excreted in urine combined with the evaluation of clinical data.
No material was available for enzyme and DNA analysis
390 J Inherit Metab Dis (2010) 33:387–396births. Data on patients with lipidoses, mucopolysaccharido-
ses, and other LSDs detected during the study period,
including carrier frequencies in the Czech population, are
summarized in Tables 1, 2 and 3, respectively. Detailed data
on the birth prevalence of specific disorders and their subtypes
can be found in Tables 4, 5 and 6.
To date, no individuals in the Czech population have been
conclusively diagnosed with Farberdisease, Schindler disease,
Danon disease, Sanfilippo D disease, galactosialidosis, fuco-
sidosis, aspartylglucosaminuria, or prosaposin, saposins, or
GM2 activator protein deficiencies.
Discussion
The overall prevalence of LSDs in the Czech population
(12.25 per 100,000), which represents a typical Central
European population, is comparable to prevalences reported
for Australia (12.9 per 100,000), the Netherlands (14 per
100,000) and Italy (12.1 per 100,000) (Meikle et al. 1999;
Poorthuis et al. 1999; Dionisi-Vici et al. 2002). The higher
prevalence of LSDs reported for the northern Portuguese
population (25 per 100,000) might reflect the relative
geographic isolation and more extensive studying of that
particular population of this region (Pinto et al. 2004). The
most frequent single LSD is Gaucher disease in the Czech
Republic, Italy and Australia, GM2 gangliosidosis in
Portugal, and Pompe disease in the Netherlands.
In the Czech population, lipidoses were most frequently
diagnosed (5.0 per 100,000 live births), followed by MPS
(3.72) and NCL (2.29). In addition to the LSD diagnoses in
Czech patients, 96 cases from Slovakia were confirmed at
our Institute during the studied period; 41% with lipidoses,
39% with MPS, and 20% with GSD II or NCLs. These
Slovakian patients have not been included in our prevalence
calculations as former Czechoslovakia was divided into two
independent states, the Czech Republic and the Slovak
Republic, in 1993. Interestingly, the four cases of prosaposin
Table 3 Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroid lipofuscinoses: comparison of data in different populations
Disease Czech Republic Other countries
No. of patients
1975–2008
a
Prevalence
per 100,000
b
Poisson 95%
confidence interval
Carrier
frequency
c×10
3
NL Portugal Australia
Prevalence per 100,000 live births
α-Mannosidosis 4 0.38 0.10–0.98 3.92 0.09 0.12 0.1
β-Mannosidosis 2 0.16 0.02–0.59 2.56 0.13 0.12 0
ISSD 1 0.02 0.0–0.13 0.97 0.07 0 0.19
Fucosidosis 0 0.05 0 0
Aspartylglucosaminuria 0 0.13 1.72 0.05
α-N-acetyl-galactosaminidase def. 0 0.2 0 0
Galactosialidosis 0 0.04 0.77 0
Mucolipidosis I 3 0.07 0.01–0.20 1.66 0.05 0 0.02
Mucolipidosis II/III 3 0.22 0.05–0.65 2.98 0.24 0.81 0.31
Mucolipidosis IV 1 0.02 0.0–0.13 0.97
Glycogenosis type II (all) 12 0.37 0.13–0.81 3.86 2 0.17 0.69
NCL 1 2 0.19 0.02–0.70 2.79 0.17
NCL 2 28 0.36 0.24–0.52 3.79 0.07
NCL 3 2 0.27 0.03–0.96 3.27 0.48
NCL 4 1 0.02 0.0–0.13 0.97
NCL 5 2 0.21 0.03–0.77 2.92
NCL 6 1 0.02 0.0–0.13 0.97 1.43
NCL 7 18 0.85 0.49–1.36 5.81
NCL unspecified
d 20 0.37 0.22–0.58
NCL (all types) 74 2.29 1.03–5.15 2.14
NL Netherlands, ISSD infantile sialic acid storage disease, NCL neuronal ceroid lipofuscinosis
aTotal number of patients diagnosed between 1975 and 2008
bData for prevalence calculations are in Table 6
cCarrier per 1 live birth
dUnspecified NCL were diagnosed on the basis of histochemical and ultrastructural examination of biopsy samples combined with the evaluation of
clinical data. No material was available for enzyme and DNA analysis
J Inherit Metab Dis (2010) 33:387–396 391deficiency so far diagnosed at our Institute came from
neighboring populations (Slovak, German) (Hulkova et al.
2001; Elleder et al. 2005;K u c h a re ta l .2009).
The birth prevalence of the most frequent LSD in the
Czech Republic, Gaucher disease, is 1.13 per 100,000 live
births, followed by Niemann-Pick C (0.91), MPS III (0.91),
MPS IV (0.73), and MPS I (0.72). Comparison of these
prevalences to those in selected foreign populations
(Tables 1, 2 and 3) is complicated by the differences in
methods used for calculation. When we compared the
calculations of prevalence in the Czech population based on
the method of Poorthuis et al. (1999) used in this study (see
“Patients and Methods”) to the method reported by Meikle
et al. (1999) (the prevalence calculated as the number of
Table 4 Lipidoses: data for calculation of birth prevalence
Disease No. of patients
1975–2008
a,b
Years
of birth
No. of
live births
No. of
patients
c
Prevalence (1 per
numbers of live births)
Prevalence
per 100,000
Carrier
frequency
d
Gaucher type I, early 12 (10) 1974–1996 3 090 902 12 257 575 0.39 254
Gaucher type I, late 29 (28) 1945–1980 5 956 028 24 248 168 0.40 249
Gaucher type II and III
e 8 (8) 1980–1998 2 352 492 8 294 062 0.34 271
Gaucher (all types) 49 44 88 397 1.13 149
Niemann-Pick A 10 (8) 1963–2002 5 480 885 10 548 089 0.18 370
Niemann-Pick B + atyp
f 13 (11) 1948–1996 7 362 146 11 669 286 0.15 409
Niemann-Pick A/B 23 21 301 327 0.33 274
Niemann-Pick C
g 54 (45) 1965–2003 5 271 310 48 109 819 0.91 166
Fabry
h 49 (24) 1945–2002 8 518 601 44 193 605 0.52 96 803
Male 4 382 068 44 99 592 1.00
n
Fabry female 78 (24) 1945–2005 8 812 161 68 129 591 0.77
Krabbe
i 15 (15) 1977–2002 3 249 150 13 249 935 0.40 250
MLD infantile 13 (11) 1970–1999 4 195 564 13 322 736 0.31 284
Juvenile 5 (4) 1970–2004 4 661 324 5 932 265 0.11 483
Adult 7 (7) 1968–1980 2 188 004 6 364 667 0.27 302
MLD (all types) 25 24 144 647 0.69 190
CESD, Wolman
j 18 (15) 1963–2002 5 480 885 15 365 392 0.27 302
GM1 gangliosidosis 13 (13) 1970–2003 4 563 660 12 380 305 0.26 308
GM2 Tay-Sachs
k 10 (10) 1971–1992 3 362 889 10 336 289 0.30 290
GM2 Sandhoff 3 (3) 1992–2007 1 594 949 3 531 650 0.19 365
Lipidoses all types 259
l/337
m 234
l/302
m 20 000 5.0
l/5.77
m 71
o
MLD Metachromatic leukodystrophy, CESD cholesteryl ester storage disease
aTotal number of patients diagnosed between 1975 and 2008
bNumber of families with particular disorder in parentheses
cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation
(e.g., patients born before 1945 were excluded). For prevalence definition, see “Patients and Methods”
dExpressed as 1 carrier per number of shown live births
eOne stillborn case
fNP type B in 6 slowly progressive visceral cases and atypical protracted neurovisceral phenotype in 7 cases [Pavlů-Pereira H, et al. J Inherit Metab Dis
2005;28:203–227]
gIncluding one case of NP type C2 [Elleder M. et al. Virchows Arch 2001;439:206–211]
hClassical phenotype in 43 male patients and cardiac variant in 6 male patients (two families) [Elleder M, et al. Cas Lek Cesk 1990;129:368–372]
iInfantile form in 12 patients, late infantile in 2 patients, and adult form in one patient [Kostalova E, et al. Ceska Slov Neurol Neurochir 2006;
69/102:200–210]
jOne infantile patient (Wolman disease) and 17 juvenile and adult cases [Elleder M, et al. Cas Lek Cesk 1999;138:719–724]
kIncluding two adult patients
lFabry females not included
mFabry females included
nMale live births
oCarrier frequency of lipidoses except for Fabry disease
392 J Inherit Metab Dis (2010) 33:387–396patients divided by the total number of live births during
the study period), the calculations resulted in underestima-
tion or overestimations of some individual disorders. This is
the case for disorders with delayed onset (e.g., frequencies
of Fabry disease were 0.52 and 1.14 per 100,000, and
frequencies of cholesterol ester storage disease were 0.27
and 0.42, if calculated using the methods of Poorthuis et al.
(1999) and Meikle et al. (1999), respectively). Also,
unavailability of some diagnostic methods during the study
period (some methods were introduced as late as the 1990s)
may explain some discrepancies found in our calculations
using the two methods. Although prevalence values for
some disorders calculated using either of the methods were
within the confidence intervals (data not shown), for other
disorders prevalence values fell outside this interval (e.g.,
the frequencies differed for MPS III C (0.42 and 0.11 per
100,000), MPS IVA (0.71 and 0.32), NCL 2 (0.36 and 0.65)
and NCL 7 (0.85 and 0.42), if calculated according to the
methods used by Poorthuis et al. (1999) and Meikle et al.
(1999), respectively).
Thus, establishment of standard rules for calculation of
birth prevalence-a defined term in clinical epidemiology-is
highly recommended. This would enable more reliable
comparison of data from different populations. Based on
our experience, the calculation of the ratio of the number of
patients to the number of live births during the patients’
births period (Poorthuis et al. 1999) fits well to the
definition of prevalence. Underestimation of the birth preva-
lence may result from lack of recognition of early clinical
signs and symptoms or phenotypic diversity, including adult
formsofthedisease(e.g.,Fabrydisease,adultKrabbedisease,
adult MLD, cholesteryl ester storage disease, and adult GSD
II). Thus, the calculated birth prevalence is probably the
lowest estimate as the diagnosis is commonly delayed for
years. Screening studies have shown that certain groups of
patients, for example individuals with renal failure on
haemodialysis, may harbor missed Fabry patients (Nakao et
al. 2003; Kotanko et al. 2004). The nationwide screening
study among 3,370 chronic haemodialysis patients in the
Czech Republic disclosed four previously unrecognized
Fabry males and one female from five unrelated families.
Subsequent family screening ascertained Fabry disease in
another 12 individuals, including 8 females (Merta et al.
2007). Patients with unexplained cardiomyopathy represent
Table 5 Mucopolysaccharidoses: data for calculation of birth prevalence
Disease No. of patients
1975–2008
a,b
Years
of birth
No. of
live births
No. of
patients
c
Prevalence (1 per
number of live births)
Prevalence
per 100,000
Carrier
frequency
d
MPS I 20
e (17) 1984–2008 2,772,559 20 138,628 0.72 186
MPS II 22 (19) 1969–2005 4,906,700 21 233,652 0.43 116,826
Male 2,520,373 21 120,018 0.83
f
MPS III A 18 (14) 1977–2006 3,648,541 17 214,620 0.47 232
MPS III B 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
MPS III C 5 (4) 1984–1992 1,179,745 5 235,949 0.42 243
MPS III (all types) 24 23 109,502 0.91 165
MPS IV A 14 (9) 1987–2003 1,826,473 13 140,498 0.71 187
MPS IV B 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
MPS IV (A + B) 15 14 136,986 0.73 185
MPS VI 2 (2) 1968–1995 4,115,057 2 2,057,529 0.05 717
MPS VII 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
MPS I–VII 84 81 34,909 2.86 93
MPS-unspecified 32 (27) 1960–1989 4,533,496 27 167,907 0.60 205
MSD 3 (1) 1962–1969 1,144,467 3 381,489 0.26 309
MPS all types 119 111 26,865 3.72 82
g
MPS mucopolysaccharidosis, MSD multiple sulphatase deficiency
aTotal number of patients diagnosed between 1975 and 2008
bNumber of families with particular disorder in parentheses
cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation
(e.g., patients born before 1945 were excluded). For prevalence definition, see “Patients and Methods”
dExpressed as 1 carrier per number of shown live births
eHurler syndrom in 16 patients, Hurler/Scheie in 2 patients and Scheie syndrom in 2 patients
fMale live births
gCarrier frequency of MPS excluding MPS II
J Inherit Metab Dis (2010) 33:387–396 393another group at risk of having Fabry disease where
screening is justified (Monserrat et al. 2007). Such LSD
screening initiatives for selected LSDs will contribute to the
identification of the true prevalence of these disorders (Spada
et al. 2006; Chien et al. 2008).
Fabry heterozygotes have not been included in the
calculation of birth prevalence in previous reports (Meikle
et al. 1999; Poorthuis et al. 1999; Pinto et al. 2004).
However, they commonly develop clinical symptoms and
severe complications, generally a few years later, as in
affected men (Deegan et al. 2006; Wilcox et al. 2008).
When we included Fabry heterozygotes in the calculations,
the prevalence of Fabry disease increased by 2.5 times to
1.29 per 100,000 live births, that of lipidoses from 5.0 to
5.77 per 100,000 and the overall prevalence of LSDs
reached 13.02 per 100,000 (Table 4). Therefore, we propose
that Fabry heterozygotes ought to be included in the
calculation of the birth prevalence of Fabry disease.
Reliable calculation of the birth prevalence is dependant
on a correctly defined pathogenic cause underlying the
condition. Recent molecular studies have provided evidence
for at least ten separate genetic loci (CLN1–CLN10) for
NCL (Peltonen et al. 2000; Siintola et al. 2007). These
new findings necessitated reclassification of our 37 cases
that had formerly been provisionally classified as NCL6
into NCL5, NCL6, and NCL7 subgroups. The latter turned
out to be of high prevalence in the Roma Gypsy population
(Kousietal. 2009). About a quarter of the NCL cases remain
unspecified due to the lack of material suitable for mutation
analysis.
Athough specific LSDs are generally reckoned to be rare
disorders, as a group of inherited metabolic disorders they are
quite common, as seen from published and our data. The
information on birth prevalencies of LSDs is available from
countries witha longtraditionofdiagnosis ofLSDs;however,
for most populations, these date are missing. Epidemiological
data on these disorders are important in genetic counselling
for calculation of the risk for the disorders in the other
members of affected families and subsequently for the public
health care systems.
Table 6 Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroidlipofuscinoses: data for calculation of birth prevalence
Disease No. of patients
1975–2008
a,b
Years
of birth
No. of
live births
No. of
patients
c
Prevalence (1 per
numbers of live births)
Prevalence
per 100,000
Carrier
frequency
d
α-Mannosidosis 4 (3) 1985–1992 1,042,804 4 260,701 0.38 255
β-Mannosidosis 2 (1) 1950–1956 1,223,386 2 611,693 0.16 391
ISSD 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
Mucolipidosis I 3
e (2) 1969–1999 4,338,729 3 1,446,243 0.07 601
Mucolipidosis II/III 3 (3) 1994–2007 1,352,219 3 450,740 0.22 336
Mucolipidosis IV 1
f 1975–2008 4,261,897 1 4,261,897 0.02 1,032
GP + ML (all types) 14 14 112,995 0.87 170
Glycogenosis type II infantile 6 (5) 1979–1999 2,614,075 6 435,679 0.23 330
Glycogenosis type II juvenile 6 (5) 1972–2002 4,167,930 6 694,655 0.14 417
Glycogenosis type II (all) 12 12 267,750 0.37 259
NCL 1 2 (2) 1970–1975 1,033,447 2 516,724 0.19 359
NCL 2 28 (25) 1949–2003 7,803,068 28 278,681 0.36 264
NCL 3 2 (2) 1979–1983 749,520 2 374,760 0.27 306
NCL 4 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
NCL 5 2 (1) 1983–1989 935,553 2 467,777 0.21 342
NCL 6 1 1975–2008 4,261,897 1 4,261,897 0.02 1,032
NCL 7 18 (16) 1985–2002 2,002,025 17 117,766 0.85 172
NCL-unspecified 20 (17) 1965–1999 4,903,214 18 272,401 0.37 261
NCL (all types) 74 71 43,551 2.29 104
ISSD infantile sialic acid storage disease, GP glycoproteinosis, ML mucolipidosis, NCL neuronal ceroid lipofuscinosis
aTotal number of patients diagnosed between 1975 and 2008
bNumber of families with particular disorder in parentheses
cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation
(e.g. patients born before 1945 were excluded). For prevalence definition see “Patients and Methods”
dExpressed as 1 carrier per number of shown live births
eOne infantile patient and two juvenile siblings with cherry-red spot myoclonus syndrome [Ledvinova J, et al. J Inherit Metab Dis 1994;17:118–119]
fAtypical case of ML IV with ocular restricted phenotype [Dobrovolny R, et al. Am J Ophthalmol 2007; 143:663–671]
394 J Inherit Metab Dis (2010) 33:387–396Importantly, awareness of the clinical aspects of these
life-threatening and progressively disabling genetic diseases
among the medical community should increase, allowing
earlier diagnosis. In turn, this will offer an opportunity for
early therapeutic intervention. Dependant on the diagnosed
disorder, such intervention may include enzyme replace-
ment therapy, bone marrow transplantation, or other current
or future therapies. Last but not least, it should be borne in
mind that genetic counselling and prenatal diagnosis in
families affected by a genetic metabolic disorder still form
the basic strategy for lowering the number of patients with
these severe disorders.
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